Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -47.25% is 18% below its 5-year average of -40.13%, around the middle of its 5-year range (-78.44%–-6.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 96.73% below its 12-month average of -24.02%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -47.25%.
RETURN ON EQUITY (ROE)
-47.25%
RETURN ON EQUITY (ROE) AVG TTM
-24.02%
RETURN ON EQUITY (ROE) AVG 3Y
-45.56%
RETURN ON EQUITY (ROE) AVG 5Y
-40.13%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-96.73%
CURRENT VS 3Y AVG
-3.71%
CURRENT VS 5Y AVG
-17.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 650 covered companies
CURRENT VS SECTOR MEDIAN
-17.53%
vs the sector median at left
Century Therapeutics, Inc.
Market Cap
$251.69M
Return on Equity (ROE)
-47.25%
TTM Avg
-24.02%
3Y Avg
-45.56%
5Y Avg
-40.13%
Market Cap
$256.72M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$246.29M
Return on Equity (ROE)
-54.67%
TTM Avg
-46.45%
3Y Avg
-41.29%
5Y Avg
-47.75%
Market Cap
$258.23M
Return on Equity (ROE)
-2.76%
TTM Avg
-22.10%
3Y Avg
-22.09%
5Y Avg
-15.95%
Market Cap
$244.52M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$246.15M
Return on Equity (ROE)
31.90%
TTM Avg
-385.06%
3Y Avg
-191.20%
5Y Avg
-142.10%
Market Cap
$244.33M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$261.24M
Return on Equity (ROE)
-26.24%
TTM Avg
-102.84%
3Y Avg
-107.17%
5Y Avg
-107.44%
Market Cap
$263.05M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $251.69M | -47.25% | -24.02% | -45.56% | -40.13% |
| AC Immune S.A. (ACIU)vs › | $256.72M | -124.67% | -101.06% | -69.44% | -56.33% |
| Quantum-Si incorporated (QSI)vs › | $246.29M | -54.67% | -46.45% | -41.29% | -47.75% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.23M | -2.76% | -22.10% | -22.09% | -15.95% |
| Invivyd, Inc. (IVVD)vs › | $244.52M | -59.27% | -136.66% | -113.26% | -53.68% |
| Q32 Bio Inc. (QTTB)vs › | $246.15M | 31.90% | -385.06% | -191.20% | -142.10% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $244.33M | -43.11% | -35.75% | -28.47% | -12.53% |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -26.24% | -102.84% | -107.17% | -107.44% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.05M | -37.12% | -62.34% | -32.67% | 8.91% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.34M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
ROE
-47.3%
ROA
-38.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -47.25% |
| 2026-03-31 | -40.71% |
| 2025-12-31 | -6.02% |
| 2025-09-30 | -15.01% |
| 2025-06-30 | -11.09% |
| 2025-03-31 | -9.13% |
| 2024-12-31 | -78.44% |
| 2024-09-30 | -66.38% |
| 2024-06-30 | -59.16% |
| 2024-03-31 | -75.03% |
| 2023-12-31 | -73.98% |
| 2023-09-30 | -58.82% |
| 2023-06-30 | -51.29% |
| 2023-03-31 | -44.98% |
| 2022-12-31 | -43.25% |
| 2022-09-30 | -38.60% |
| 2022-06-30 | -34.28% |
| 2022-03-31 | -29.74% |
| 2021-12-31 | -24.18% |
| 2021-09-30 | -19.66% |
| 2021-06-30 | -15.69% |
